Hepatitis C News and Research

Latest Hepatitis C News and Research

BioCryst second quarter total revenues decrease to $3.7 million

BioCryst Pharmaceuticals, Inc. announced financial results for the second quarter and six months ended June 30, 2011.

4 Aug 2011

NanoViricides to apply 'lead optimization technology' to anti-HIV candidate

NanoViricides, Inc. recently reported on its completed animal study that compared its lead anti-HIV candidate HIVCide™, to a HAART (highly active anti retroviral therapy) triple drug cocktail. The cocktail used therein is based on an anti-HIV therapeutic protocol in current practice. The Company has received numerous inquiries for simplified explanation of the results.

3 Aug 2011

Needle-free nanopatch vaccine delivery system

The needle-free nanopatch vaccine delivery system is coming soon after a consortium of investors put up $15 million for its development. The money will enable University of Queensland's Professor Mark Kendall to continue his work on the technology. It is described as the biggest breakthrough in vaccine delivery since the invention of the syringe more than 150 years ago.

3 Aug 2011

Alnylam second quarter revenue decreases to $20.6 million

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter 2011, and company highlights.

From Precision NanoSystems Inc. 2 Aug 2011

Merck reports worldwide sales of $12.2 billion for second quarter 2011

Merck, known as MSD outside the United States and Canada, today announced financial results for the second quarter of 2011.

29 Jul 2011

ELPA, WHA announce educational program for hepatitis B patients

The European Liver Patients Association (ELPA) and the World Hepatitis Alliance (WHA), announced today on the 4th annual World Hepatitis Day that 'PATH B - "Patients and Professionals Acting Together for Hepatitis B" - My journey with chronic hepatitis B', a comprehensive educational resource designed to improve the lives of people living with chronic hepatitis B, is to be launched in August 2011.

29 Jul 2011

WHO marks first-ever World Hepatitis Day

The WHO on Thursday marked the first-ever World Hepatitis Day, recognizing a disease that affects nearly one of every three people in the world, the U.N. News Centre reports.

29 Jul 2011

Tips to make family vacations less hazardous for kids and parents

Family vacations live in infamy. Sometimes it's for the lasting memories of family bonding and new wonders experienced together, and sometimes for the horrors of just trying to get to a destination.

29 Jul 2011

Hepatitis on the rise

According to the World Health Organization (WHO), the battle is on to fight the rising numbers of hepatitis B cases. Medical experts are calling for global action to tackle the viruses that cause the liver disease hepatitis. The first worldwide estimates in drug users show 10 million have hepatitis C while 1.3 million have hepatitis B.

29 Jul 2011

ELPA, WHA to launch PATH B programme for patients with chronic hepatitis B

28 Jul 2011

OR models verify cost effectiveness of hepatitis B interventions

With hepatitis B infecting as many as 10% of people of Asian descent, operations researchers collaborated with a liver transplant surgeon to develop mathematical models that verified the cost effectiveness of hepatitis B interventions.

27 Jul 2011

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has announced that it received positive data from ENABLE-1, the first of two Phase III studies examining Promacta in patients with hepatitis C-related thrombocytopenia, and that full data will be released at an upcoming scientific conference.

27 Jul 2011

Kadmon, Dyax enter license agreement for antibody phage display libraries

Dyax Corp. and Kadmon Corporation, LLC announced today that Dyax has granted Kadmon a non-exclusive license to Dyax's proprietary "gold-standard" antibody phage display libraries for the discovery and development of therapeutic antibodies.

26 Jul 2011

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

NanoViricides, Inc. reports that its lead anti-HIV candidate achieved anti-HIV efficacy equivalent to a HAART triple drug cocktail in its recently completed animal study.

25 Jul 2011

MHCC, U of C partner to evaluate 'The Mind Course' for medical students

The Mental Health Commission of Canada (MHCC) has partnered with the University of Calgary's Faculty of Medicine to evaluate a special course for second year medical students which aims to reduce the prejudice and discrimination associated with mental illness.

25 Jul 2011

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Incidence rates of hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC) have increased in the U.S. This population-based study publishing in the August issue of Hepatology, a journal of the American Association for the Study of Liver Diseases, found that metabolic syndrome significantly increases risk of developing these primary liver cancers.

22 Jul 2011

Hepatitis B immunization for health care students may fall short of current recommendations

A study in the August issue of Infection Control and Hospital Epidemiology, the journal of the Society for Healthcare Epidemiology of America (SHEA), suggests that documentation of hepatitis B vaccination for health care students may fall short of current recommendations.

22 Jul 2011

HIV-infected MSM more likely to contract HCV through sex

Sexual transmission of hepatitis C virus (HCV) is considered rare. But a new study by researchers at Mount Sinai School of Medicine, working with the Centers for Disease Control and Prevention (CDC), provides substantial evidence that men with HIV who have sex with other men (MSM) are at increased risk for contracting HCV through sex.

22 Jul 2011

Metabolic syndrome linked to increased risk of primary liver cancers

22 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Hepatitis C News and Research

Latest Hepatitis C News and Research

BioCryst second quarter total revenues decrease to $3.7 million

NanoViricides to apply 'lead optimization technology' to anti-HIV candidate

Needle-free nanopatch vaccine delivery system

Alnylam second quarter revenue decreases to $20.6 million

Merck reports worldwide sales of $12.2 billion for second quarter 2011

ELPA, WHA announce educational program for hepatitis B patients

WHO marks first-ever World Hepatitis Day

Tips to make family vacations less hazardous for kids and parents

Hepatitis on the rise

ELPA, WHA to launch PATH B programme for patients with chronic hepatitis B

OR models verify cost effectiveness of hepatitis B interventions

Positive data from two GSK's Promacta Phase III studies on hepatitis C-related thrombocytopenia

Kadmon, Dyax enter license agreement for antibody phage display libraries

Nanoviricides lead anti-HIV candidate as good as HAART cocktail therapy

MHCC, U of C partner to evaluate 'The Mind Course' for medical students

Metabolic syndrome increases risk of developing HCC and ICC primary liver cancers

Hepatitis B immunization for health care students may fall short of current recommendations

HIV-infected MSM more likely to contract HCV through sex

Metabolic syndrome linked to increased risk of primary liver cancers

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Hepatitis C News and Research

Latest Hepatitis C News and Research

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Newsletters you may be interested in